First National Bank of Omaha Has $5.28 Million Stock Holdings in Humana Inc (NYSE:HUM)

First National Bank of Omaha lifted its stake in shares of Humana Inc (NYSE:HUM) by 0.5% during the third quarter, Holdings Channel reports. The firm owned 20,632 shares of the insurance provider’s stock after purchasing an additional 103 shares during the quarter. First National Bank of Omaha’s holdings in Humana were worth $5,275,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in HUM. Cornerstone Advisors Inc. raised its position in Humana by 9.9% during the third quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock valued at $99,000 after buying an additional 35 shares during the period. Lindbrook Capital LLC raised its position in Humana by 12.0% during the third quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock valued at $84,000 after buying an additional 35 shares during the period. Regentatlantic Capital LLC raised its position in Humana by 0.4% during the second quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after buying an additional 42 shares during the period. Ballentine Partners LLC raised its position in Humana by 2.5% during the third quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock valued at $448,000 after buying an additional 42 shares during the period. Finally, Cim Investment Mangement Inc. raised its position in Humana by 4.3% during the second quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock valued at $298,000 after buying an additional 46 shares during the period. 92.93% of the stock is currently owned by institutional investors.

Several research analysts recently weighed in on HUM shares. Canaccord Genuity reissued a “buy” rating on shares of Humana in a research report on Monday, October 21st. Citigroup upped their price target on Humana from $340.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a research report on Friday. JPMorgan Chase & Co. upped their target price on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald raised Humana from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $300.00 to $345.00 in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have issued a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average price target of $335.45.

In other news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.54% of the company’s stock.

Shares of HUM traded up $2.80 during trading hours on Friday, hitting $317.94. 980,852 shares of the company were exchanged, compared to its average volume of 901,090. The company has a market cap of $39.82 billion, a PE ratio of 21.85, a PEG ratio of 1.27 and a beta of 0.85. The firm’s 50 day moving average is $276.72 and its 200-day moving average is $270.55. Humana Inc has a 52 week low of $225.65 and a 52 week high of $353.05. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to the consensus estimate of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.58 EPS. As a group, equities analysts forecast that Humana Inc will post 17.75 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. The ex-dividend date is Monday, December 30th. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. Humana’s dividend payout ratio (DPR) is presently 15.12%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: What is an Initial Public Offering (IPO)?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.